<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE ALGORITHM SYSTEM "https://cms.hivdb.org/prod/downloads/asi/ASI2.2.dtd">
<ALGORITHM>
  <ALGNAME>HIVDB-HIV2</ALGNAME>
  <ALGVERSION>9.0a2</ALGVERSION>
  <ALGDATE>2020-02-07</ALGDATE>
  <DEFINITIONS>
    <GENE_DEFINITION>
      <NAME>PR</NAME>
      <DRUGCLASSLIST>PI</DRUGCLASSLIST>
    </GENE_DEFINITION>
    <GENE_DEFINITION>
      <NAME>RT</NAME>
      <DRUGCLASSLIST>NRTI</DRUGCLASSLIST>
    </GENE_DEFINITION>
    <GENE_DEFINITION>
      <NAME>IN</NAME>
      <DRUGCLASSLIST>INSTI</DRUGCLASSLIST>
    </GENE_DEFINITION>
    <LEVEL_DEFINITION>
      <ORDER>1</ORDER>
      <ORIGINAL>Susceptible</ORIGINAL>
      <SIR>S</SIR>
    </LEVEL_DEFINITION>
    <LEVEL_DEFINITION>
      <ORDER>2</ORDER>
      <ORIGINAL>Potential Low-Level Resistance</ORIGINAL>
      <SIR>S</SIR>
    </LEVEL_DEFINITION>
    <LEVEL_DEFINITION>
      <ORDER>3</ORDER>
      <ORIGINAL>Low-Level Resistance</ORIGINAL>
      <SIR>I</SIR>
    </LEVEL_DEFINITION>
    <LEVEL_DEFINITION>
      <ORDER>4</ORDER>
      <ORIGINAL>Intermediate Resistance</ORIGINAL>
      <SIR>I</SIR>
    </LEVEL_DEFINITION>
    <LEVEL_DEFINITION>
      <ORDER>5</ORDER>
      <ORIGINAL>High-Level Resistance</ORIGINAL>
      <SIR>R</SIR>
    </LEVEL_DEFINITION>
    <DRUGCLASS>
      <NAME>NRTI</NAME>
      <DRUGLIST>ABC,AZT,D4T,DDI,FTC,3TC,TDF</DRUGLIST>
    </DRUGCLASS>
    <DRUGCLASS>
      <NAME>PI</NAME>
      <DRUGLIST>ATV/r,DRV/r,FPV/r,IDV/r,LPV/r,NFV,SQV/r,TPV/r</DRUGLIST>
    </DRUGCLASS>
    <DRUGCLASS>
      <NAME>INSTI</NAME>
      <DRUGLIST>BIC,DTG,EVG,RAL</DRUGLIST>
    </DRUGCLASS>
    <GLOBALRANGE><![CDATA[(-INF TO 9 => 1,  10 TO 14 => 2,  15 TO 29 => 3,  30 TO 59 => 4,  60 TO INF => 5)]]></GLOBALRANGE>
    <COMMENT_DEFINITIONS>
      <COMMENT_STRING id="HIV2AIN118R">
        <TEXT><![CDATA[G118R is an uncommon HIV-1-associated drug-resistance mutation which has not yet been reported in HIV-2 infected patients.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN121Y">
        <TEXT><![CDATA[F121Y is an uncommon HIV-1-associated drug-resistance mutation which has not yet been reported in HIV-2 infected patients.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN140SAC">
        <TEXT><![CDATA[G140S is a nonpolymorphic HIV-1 associated drug-resistance mutation which is also selected by INSTIs in HIV-2-infected persons]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN143CR">
        <TEXT><![CDATA[Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN147G">
        <TEXT><![CDATA[S147G is a non-polymorphic HIV-1-associated drug-resistance mutation that has also been reported in INSTI-experienced persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN148HKR">
        <TEXT><![CDATA[Q148H/K/R are nonpolymorphic HIV-1 associated drug-resistance mutation which are also selected by INSTIs in HIV-2-infected persons]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN153G">
        <TEXT><![CDATA[S153YF are extremely rare nonpolymorphic HIV-1-associated INSTI-resistance mutations. A153G is a nonpolymorphic HIV-2 mutation that is selected by INSTIs usually in combination with N155H]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN155H">
        <TEXT><![CDATA[N155H is a nonpolymorphic HIV-1 associated drug-resistance mutation which is also commonly selected by INSTIs in HIV-2-infected persons]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN231_">
        <TEXT><![CDATA[Among HIV-2 isolates, amino  acid insertions at position 231 are selected by INSTIs and associated with markedly reduced INSTI susceptibility.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN263K">
        <TEXT><![CDATA[R263K is a nonpolymorphic HIV-1-associated drug-resistance mutation which has also been reported in HIV-2 infected INSTI-experienced persons. ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN51Y">
        <TEXT><![CDATA[H51Y is an uncommon HIV-1-associated drug-resistance mutation which has also been selected by INSTIs in HIV-2 infected patients.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN66AIK">
        <TEXT><![CDATA[T66AIK are HIV-1-associated drug-resistance mutation which have  not been reported in HIV-2 infected patients.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN84V">
        <TEXT><![CDATA[I84V is a polymorphic HIV-2 associated mutation that occurs significantly more commonly in INSTI-experienced compared with INSTI-naïve persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN92GAQ">
        <TEXT><![CDATA[E92Q is an HIV-1-associated drug resistance mutations which is also commonly selected by INSTIs in HIV-2 infected persons. E92G/A have also been reported in INSTI-experienced HIV-2-infected persons]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2AIN97A">
        <TEXT><![CDATA[Among HIV-1 isolates, T97A is a minimally polymorphic accessory INSTI-selected mutation. Among HIV-2 isolates, T97A is a nonpolymorphic common INSTI-selected mutation.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR10I">
        <TEXT><![CDATA[V10I is a minimally polymorphic mutation that occurs significantly more commonly in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR23I">
        <TEXT><![CDATA[L23I is an uncommon non-polymorphic HIV-1 associated PI-resistance mutation.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR30N">
        <TEXT><![CDATA[D30N is a non-polymorphic mutation that causes high-level HIV-1 resistance to NFV.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR33I">
        <TEXT><![CDATA[V33I is a minimally polymorphic mutation that occurs significantly more commonly in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR45R">
        <TEXT><![CDATA[K45R is a minimally polymorphic mutation that occurs significantly more commonly in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR47A">
        <TEXT><![CDATA[V47A is a non-polymorphic common PI-selected mutation that reduces HIV-2 susceptibility to LPV and other PIs.  ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR48VA">
        <TEXT><![CDATA[G48VA are non-polymorphic PI-selected HIV-2 mutations]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR50L">
        <TEXT><![CDATA[I50L is a non-polymorphic HIV-2 mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR50V">
        <TEXT><![CDATA[I50V is a non-polymorphic PI-selected mutation that reduces HIV-2 susceptibility to LPV and other PIs.  ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR53Y">
        <TEXT><![CDATA[F53Y is a nonpolymorphic PI-selected HIV-2 mutation]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR54L">
        <TEXT><![CDATA[I54L is a nonpolymorphic PI-selected mutation.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR54M">
        <TEXT><![CDATA[I54M is a non-polymorphic common PI-selected mutation.  ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR56V">
        <TEXT><![CDATA[T56V is a common nonpolymrophic mutation that occurs significantly more commonly in HIV-2 isolates from PI-treated vs. PI-naïve isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR71I">
        <TEXT><![CDATA[V71I is a common polymorphic mutation that occurs significantly more commonly in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR73G">
        <TEXT><![CDATA[A73G is a nonpolymorphic mutation that occurs significantly more commonoly in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR82F">
        <TEXT><![CDATA[I82F is a non-polymorphic common PI-selected mutations that reduces HIV-2 susceptibility to LPV and other PIs.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR82LM">
        <TEXT><![CDATA[I82LM are nonpolymorphic PI-selected HIV-2 mutations.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR84V">
        <TEXT><![CDATA[I84V is a non-polymorphic PI-selected HIV-2 mutation.  ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR85L">
        <TEXT><![CDATA[I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR88D">
        <TEXT><![CDATA[N88D is a nonpolymorphic HIV-1-associated PI resistance mutation that has been reported in one PI-treated HIV-2 isolate.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR90M">
        <TEXT><![CDATA[L90M is a non-polymorphic PI-selected HIV-2 mutation. ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR95V">
        <TEXT><![CDATA[M95V is a nonpolymorphic mutations that occurs significantly more common in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2APR99F">
        <TEXT><![CDATA[L99F is a nonpolymorphic mutations that occurs significantly more common in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART111I">
        <TEXT><![CDATA[V111I is a common polymorphic mutation that occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART115F">
        <TEXT><![CDATA[Y11F is associated with reduced susceptibility to each of the NRTIs]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART116Y">
        <TEXT><![CDATA[F116Y is an accessory HIV-1-associated mutation that usually occurs in combination with the multi-NRTI resistance mutation Q151M. It has not been associated with NRTI therapy in HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART151M">
        <TEXT><![CDATA[Q151M causes high-level resistance to each of the NRTIs.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART184VI">
        <TEXT><![CDATA[M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART195N">
        <TEXT><![CDATA[D195N is a slighly polymorphic HIV-2 mutation that occurs with increased frequency in NRTI-treated persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART210ACDEFGHIKLMPQRSTVWY_">
        <TEXT><![CDATA[210W is an HIV-1 associated TAM. The HIV-2 consensus at this position is N. Mutations at this position have not been selected by NRTIs in HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART214L">
        <TEXT><![CDATA[F214L is a slighly polymorphic HIV-2 mutation that occurs with increased frequency in NRTI-treated persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART215YF">
        <TEXT><![CDATA[S215Y/F occur significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons but their effects on HIV-2 susceptibility to NRTIs is uncertain.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART219ACDFGHIKLMNPQRSTVWY_">
        <TEXT><![CDATA[219QENR are HIV-1 associated TAMs. The HIV-2 consensus  at this position is E. Mutations at this position have not been selected by NRTIs in HIV-2 isolates. ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART40R">
        <TEXT><![CDATA[K40R occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART41L">
        <TEXT><![CDATA[M41L is an HIV-1 associated TAM that has not been selected by NRTIs in HIV-2-infected persons and has not been associated with reduced HIV-2 susceptibility to NRTIs.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART62V">
        <TEXT><![CDATA[A62V occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART65EN">
        <TEXT><![CDATA[K65R occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons and is associated with reduced susceptibility to XXX.K65N/E are mutations that have rarely been selected by TDF, ABC, and d4T in HIV-1 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART65R">
        <TEXT><![CDATA[K65R occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons and is associated with reduced susceptibility to XXX.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART67NGESTH">
        <TEXT><![CDATA[D67 mutations are commonly occurring HIV-1-assocated TAMs that are not selected in HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART69-">
        <TEXT><![CDATA[Deletions in the Beta3-Beta4 loop are associated with reduced HIV-1 susceptibility to each of the NRTIs but they have not been reported in HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART69S">
        <TEXT><![CDATA[N69S is a slighly polymorphic HIV-2 mutation that occurs with increased frequency in NRTI-treated persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART69_">
        <TEXT><![CDATA[Insertions in the Beta3-Beta4 loop are associated with reduced HIV-1 susceptibility to each of the NRTIs but they have not been reported in HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART70N">
        <TEXT><![CDATA[K70N occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons but its effects on HIV-2 susceptibility to NRTIs is uncertain.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART70R">
        <TEXT><![CDATA[K70R occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons but its effects on HIV-2 susceptibility to NRTIs is uncertain.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART74VI">
        <TEXT><![CDATA[L74VI are common HIV-1-associated NRTI-resistance mutations that have not been reported in HIV-2 sequences.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART75V">
        <TEXT><![CDATA[I75V occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons but its effects on HIV-2 susceptibility to NRTIs is uncertain.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2ART77L">
        <TEXT><![CDATA[F77L is an accessory HIV-1-associated mutation that usually occurs in combination with the multi-NRTI resistance mutation Q151M. It has not been associated with NRTI therapy in HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN118R">
        <TEXT><![CDATA[G118R is an uncommon HIV-1-associated drug-resistance mutation which has not yet been reported in HIV-2 infected patients.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN121Y">
        <TEXT><![CDATA[F121Y is an uncommon HIV-1-associated drug-resistance mutation which has not yet been reported in HIV-2 infected patients.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN140SAC">
        <TEXT><![CDATA[G140S is a nonpolymorphic HIV-1 associated drug-resistance mutation which is also selected by INSTIs in HIV-2-infected persons]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN143CR">
        <TEXT><![CDATA[Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN147G">
        <TEXT><![CDATA[S147G is a non-polymorphic HIV-1-associated drug-resistance mutation that has also been reported in INSTI-experienced persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN148HKR">
        <TEXT><![CDATA[Q148H/K/R are nonpolymorphic HIV-1 associated drug-resistance mutation which are also selected by INSTIs in HIV-2-infected persons]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN153G">
        <TEXT><![CDATA[S153YF are extremely rare nonpolymorphic HIV-1-associated INSTI-resistance mutations. A153G is a nonpolymorphic HIV-2 mutation that is selected by INSTIs usually in combination with N155H]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN155H">
        <TEXT><![CDATA[N155H is a nonpolymorphic HIV-1 associated drug-resistance mutation which is also commonly selected by INSTIs in HIV-2-infected persons]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN231_">
        <TEXT><![CDATA[Among HIV-2 isolates, amino  acid insertions at position 231 are selected by INSTIs and associated with markedly reduced INSTI susceptibility.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN263K">
        <TEXT><![CDATA[R263K is a nonpolymorphic HIV-1-associated drug-resistance mutation which has also been reported in HIV-2 infected INSTI-experienced persons. ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN51Y">
        <TEXT><![CDATA[H51Y is an uncommon HIV-1-associated drug-resistance mutation which has also been selected by INSTIs in HIV-2 infected patients.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN66AIK">
        <TEXT><![CDATA[T66AIK are HIV-1-associated drug-resistance mutation which have  not been reported in HIV-2 infected patients.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN84V">
        <TEXT><![CDATA[I84V is a polymorphic HIV-2 associated mutation that occurs significantly more commonly in INSTI-experienced compared with INSTI-naïve persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN92GAQ">
        <TEXT><![CDATA[E92Q is an HIV-1-associated drug resistance mutations which is also commonly selected by INSTIs in HIV-2 infected persons. E92G/A have also been reported in INSTI-experienced HIV-2-infected persons]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BIN97A">
        <TEXT><![CDATA[Among HIV-1 isolates, T97A is a minimally polymorphic accessory INSTI-selected mutation. Among HIV-2 isolates, T97A is a nonpolymorphic common INSTI-selected mutation.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR10I">
        <TEXT><![CDATA[V10I is a minimally polymorphic mutation that occurs significantly more commonly in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR23I">
        <TEXT><![CDATA[L23I is an uncommon non-polymorphic HIV-1 associated PI-resistance mutation.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR30N">
        <TEXT><![CDATA[D30N is a non-polymorphic mutation that causes high-level HIV-1 resistance to NFV.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR33I">
        <TEXT><![CDATA[V33I is a minimally polymorphic mutation that occurs significantly more commonly in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR45R">
        <TEXT><![CDATA[K45R is a minimally polymorphic mutation that occurs significantly more commonly in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR47A">
        <TEXT><![CDATA[V47A is a non-polymorphic common PI-selected mutation that reduces HIV-2 susceptibility to LPV and other PIs.  ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR48VA">
        <TEXT><![CDATA[G48VA are non-polymorphic PI-selected HIV-2 mutations]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR50L">
        <TEXT><![CDATA[I50L is a non-polymorphic HIV-2 mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR50V">
        <TEXT><![CDATA[I50V is a non-polymorphic PI-selected mutation that reduces HIV-2 susceptibility to LPV and other PIs.  ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR53Y">
        <TEXT><![CDATA[F53Y is a nonpolymorphic PI-selected HIV-2 mutation]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR54L">
        <TEXT><![CDATA[I54L is a nonpolymorphic PI-selected mutation.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR54M">
        <TEXT><![CDATA[I54M is a non-polymorphic common PI-selected mutation.  ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR56V">
        <TEXT><![CDATA[T56V is a common nonpolymrophic mutation that occurs significantly more commonly in HIV-2 isolates from PI-treated vs. PI-naïve isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR71I">
        <TEXT><![CDATA[V71I is a common polymorphic mutation that occurs significantly more commonly in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR73G">
        <TEXT><![CDATA[A73G is a nonpolymorphic mutation that occurs significantly more commonoly in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR82F">
        <TEXT><![CDATA[I82F is a non-polymorphic common PI-selected mutations that reduces HIV-2 susceptibility to LPV and other PIs.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR82LM">
        <TEXT><![CDATA[I82LM are nonpolymorphic PI-selected HIV-2 mutations.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR84V">
        <TEXT><![CDATA[I84V is a non-polymorphic PI-selected HIV-2 mutation.  ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR85L">
        <TEXT><![CDATA[I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR88D">
        <TEXT><![CDATA[N88D is a nonpolymorphic HIV-1-associated PI resistance mutation that has been reported in one PI-treated HIV-2 isolate.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR90M">
        <TEXT><![CDATA[L90M is a non-polymorphic PI-selected HIV-2 mutation. ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR95V">
        <TEXT><![CDATA[M95V is a nonpolymorphic mutations that occurs significantly more common in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BPR99F">
        <TEXT><![CDATA[L99F is a nonpolymorphic mutations that occurs significantly more common in PI-treated than PI-naïve HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT111I">
        <TEXT><![CDATA[V111I is a common polymorphic mutation that occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT115F">
        <TEXT><![CDATA[Y11F is associated with reduced susceptibility to each of the NRTIs]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT116Y">
        <TEXT><![CDATA[F116Y is an accessory HIV-1-associated mutation that usually occurs in combination with the multi-NRTI resistance mutation Q151M. It has not been associated with NRTI therapy in HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT151M">
        <TEXT><![CDATA[Q151M causes high-level resistance to each of the NRTIs.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT184VI">
        <TEXT><![CDATA[M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT195N">
        <TEXT><![CDATA[D195N is a slighly polymorphic HIV-2 mutation that occurs with increased frequency in NRTI-treated persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT210ACDEFGHIKLMPQRSTVWY_">
        <TEXT><![CDATA[210W is an HIV-1 associated TAM. The HIV-2 consensus at this position is N. Mutations at this position have not been selected by NRTIs in HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT214L">
        <TEXT><![CDATA[F214L is a slighly polymorphic HIV-2 mutation that occurs with increased frequency in NRTI-treated persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT215YF">
        <TEXT><![CDATA[S215Y/F occur significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons but their effects on HIV-2 susceptibility to NRTIs is uncertain.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT219ACDFGHIKLMNPQRSTVWY_">
        <TEXT><![CDATA[219QENR are HIV-1 associated TAMs. The HIV-2 consensus  at this position is E. Mutations at this position have not been selected by NRTIs in HIV-2 isolates. ]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT40R">
        <TEXT><![CDATA[K40R occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT41L">
        <TEXT><![CDATA[M41L is an HIV-1 associated TAM that has not been selected by NRTIs in HIV-2-infected persons and has not been associated with reduced HIV-2 susceptibility to NRTIs.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT62V">
        <TEXT><![CDATA[A62V occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT65EN">
        <TEXT><![CDATA[K65R occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons and is associated with reduced susceptibility to XXX.K65N/E are mutations that have rarely been selected by TDF, ABC, and d4T in HIV-1 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT65R">
        <TEXT><![CDATA[K65R occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons and is associated with reduced susceptibility to XXX.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT67NGESTH">
        <TEXT><![CDATA[D67 mutations are commonly occurring HIV-1-assocated TAMs that are not selected in HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT69-">
        <TEXT><![CDATA[Deletions in the Beta3-Beta4 loop are associated with reduced HIV-1 susceptibility to each of the NRTIs but they have not been reported in HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT69S">
        <TEXT><![CDATA[N69S is a slighly polymorphic HIV-2 mutation that occurs with increased frequency in NRTI-treated persons.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT69_">
        <TEXT><![CDATA[Insertions in the Beta3-Beta4 loop are associated with reduced HIV-1 susceptibility to each of the NRTIs but they have not been reported in HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT70N">
        <TEXT><![CDATA[K70N occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons but its effects on HIV-2 susceptibility to NRTIs is uncertain.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT70R">
        <TEXT><![CDATA[K70R occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons but its effects on HIV-2 susceptibility to NRTIs is uncertain.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT74VI">
        <TEXT><![CDATA[L74VI are common HIV-1-associated NRTI-resistance mutations that have not been reported in HIV-2 sequences.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT75V">
        <TEXT><![CDATA[I75V occurs significantly more commonly in HIV-2 sequences from NRTI-treated than NRTI-naïve persons but its effects on HIV-2 susceptibility to NRTIs is uncertain.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
      <COMMENT_STRING id="HIV2BRT77L">
        <TEXT><![CDATA[F77L is an accessory HIV-1-associated mutation that usually occurs in combination with the multi-NRTI resistance mutation Q151M. It has not been associated with NRTI therapy in HIV-2 isolates.]]></TEXT>
        <SORT_TAG>1</SORT_TAG>
      </COMMENT_STRING>
    </COMMENT_DEFINITIONS>
  </DEFINITIONS>
  <DRUG>
    <NAME>ABC</NAME>
    <FULLNAME>abacavir</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>AZT</NAME>
    <FULLNAME>zidovudine</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>D4T</NAME>
    <FULLNAME>stavudine</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>DDI</NAME>
    <FULLNAME>didanosine</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>FTC</NAME>
    <FULLNAME>emtricitabine</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>3TC</NAME>
    <FULLNAME>lamivudine</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>TDF</NAME>
    <FULLNAME>tenofovir</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>ATV/r</NAME>
    <FULLNAME>atazanavir/r</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>DRV/r</NAME>
    <FULLNAME>darunavir/r</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>FPV/r</NAME>
    <FULLNAME>fosamprenavir/r</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>IDV/r</NAME>
    <FULLNAME>indinavir/r</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>LPV/r</NAME>
    <FULLNAME>lopinavir/r</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>NFV</NAME>
    <FULLNAME>nelfinavir</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>SQV/r</NAME>
    <FULLNAME>saquinavir/r</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>TPV/r</NAME>
    <FULLNAME>tipranavir/r</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>BIC</NAME>
    <FULLNAME>bictegravir</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>DTG</NAME>
    <FULLNAME>dolutegravir</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>EVG</NAME>
    <FULLNAME>elvitegravir</FULLNAME>
  </DRUG>
  <DRUG>
    <NAME>RAL</NAME>
    <FULLNAME>raltegravir</FULLNAME>
  </DRUG>
  <MUTATION_COMMENTS>
    <GENE>
      <NAME>IN</NAME>
      <RULE>
        <CONDITION>118R</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN118R"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>121Y</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN121Y"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>140SAC</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN140SAC"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>143CR</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN143CR"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>147G</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN147G"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>148HKR</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN148HKR"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>153G</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN153G"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>155H</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN155H"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>231i</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN231_"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>263K</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN263K"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>51Y</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN51Y"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>66AIK</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN66AIK"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>84V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN84V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>92GAQ</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN92GAQ"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>97A</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2AIN97A"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>118R</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN118R"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>121Y</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN121Y"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>140SAC</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN140SAC"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>143CR</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN143CR"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>147G</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN147G"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>148HKR</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN148HKR"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>153G</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN153G"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>155H</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN155H"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>231i</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN231_"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>263K</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN263K"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>51Y</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN51Y"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>66AIK</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN66AIK"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>84V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN84V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>92GAQ</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN92GAQ"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>97A</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BIN97A"/>
        </ACTIONS>
      </RULE>
    </GENE>
    <GENE>
      <NAME>PR</NAME>
      <RULE>
        <CONDITION>10I</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR10I"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>23I</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR23I"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>30N</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR30N"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>33I</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR33I"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>45R</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR45R"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>47A</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR47A"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>48VA</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR48VA"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>50L</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR50L"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>50V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR50V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>53Y</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR53Y"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>54L</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR54L"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>54M</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR54M"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>56V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR56V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>71I</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR71I"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>73G</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR73G"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>82F</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR82F"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>82LM</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR82LM"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>84V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR84V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>85L</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR85L"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>88D</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR88D"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>90M</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR90M"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>95V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR95V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>99F</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2APR99F"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>10I</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR10I"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>23I</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR23I"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>30N</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR30N"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>33I</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR33I"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>45R</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR45R"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>47A</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR47A"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>48VA</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR48VA"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>50L</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR50L"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>50V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR50V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>53Y</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR53Y"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>54L</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR54L"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>54M</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR54M"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>56V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR56V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>71I</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR71I"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>73G</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR73G"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>82F</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR82F"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>82LM</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR82LM"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>84V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR84V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>85L</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR85L"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>88D</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR88D"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>90M</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR90M"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>95V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR95V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>99F</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BPR99F"/>
        </ACTIONS>
      </RULE>
    </GENE>
    <GENE>
      <NAME>RT</NAME>
      <RULE>
        <CONDITION>111I</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART111I"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>115F</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART115F"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>116Y</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART116Y"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>151M</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART151M"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>184VI</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART184VI"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>195N</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART195N"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>210ACDEFGHIKLMPQRSTVWYi</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART210ACDEFGHIKLMPQRSTVWY_"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>214L</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART214L"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>215YF</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART215YF"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>219ACDFGHIKLMNPQRSTVWYi</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART219ACDFGHIKLMNPQRSTVWY_"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>40R</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART40R"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>41L</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART41L"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>62V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART62V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>65EN</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART65EN"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>65R</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART65R"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>67NGESTH</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART67NGESTH"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>69d</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART69-"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>69S</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART69S"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>69i</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART69_"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>70N</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART70N"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>70R</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART70R"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>74VI</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART74VI"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>75V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART75V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>77L</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2ART77L"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>111I</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT111I"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>115F</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT115F"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>116Y</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT116Y"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>151M</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT151M"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>184VI</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT184VI"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>195N</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT195N"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>210ACDEFGHIKLMPQRSTVWYi</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT210ACDEFGHIKLMPQRSTVWY_"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>214L</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT214L"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>215YF</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT215YF"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>219ACDFGHIKLMNPQRSTVWYi</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT219ACDFGHIKLMNPQRSTVWY_"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>40R</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT40R"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>41L</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT41L"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>62V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT62V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>65EN</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT65EN"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>65R</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT65R"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>67NGESTH</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT67NGESTH"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>69d</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT69-"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>69S</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT69S"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>69i</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT69_"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>70N</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT70N"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>70R</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT70R"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>74VI</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT74VI"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>75V</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT75V"/>
        </ACTIONS>
      </RULE>
      <RULE>
        <CONDITION>77L</CONDITION>
        <ACTIONS>
          <COMMENT ref="HIV2BRT77L"/>
        </ACTIONS>
      </RULE>
    </GENE>
  </MUTATION_COMMENTS>
  <RESULT_COMMENTS/>
</ALGORITHM>
